Cargando…
Copy number variations in primary tumor, serum and lymph node metastasis of bladder cancer patients treated with radical cystectomy
The aim of the present study was to analyze copy number variations (CNV) of multiple oncogenes and tumor suppressor genes in genomic DNA from primary tumor tissue, lymph node metastasis and cell-free DNA (cfDNA) from serum of 72 urothelial carcinoma of bladder (UCB) patients treated with radical cys...
Autores principales: | , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7725833/ https://www.ncbi.nlm.nih.gov/pubmed/33298978 http://dx.doi.org/10.1038/s41598-020-75869-x |
_version_ | 1783620785398611968 |
---|---|
author | Soave, Armin Kluwe, Lan Yu, Hang Rink, Michael Gild, Philipp Vetterlein, Malte W. Marks, Philipp Sauter, Guido Fisch, Margit Meyer, Christian P. Ludwig, Tim Dahlem, Roland Minner, Sarah Pantel, Klaus Steinbach, Bettina Schwarzenbach, Heidi |
author_facet | Soave, Armin Kluwe, Lan Yu, Hang Rink, Michael Gild, Philipp Vetterlein, Malte W. Marks, Philipp Sauter, Guido Fisch, Margit Meyer, Christian P. Ludwig, Tim Dahlem, Roland Minner, Sarah Pantel, Klaus Steinbach, Bettina Schwarzenbach, Heidi |
author_sort | Soave, Armin |
collection | PubMed |
description | The aim of the present study was to analyze copy number variations (CNV) of multiple oncogenes and tumor suppressor genes in genomic DNA from primary tumor tissue, lymph node metastasis and cell-free DNA (cfDNA) from serum of 72 urothelial carcinoma of bladder (UCB) patients treated with radical cystectomy (RC), using multiplex ligation-dependent probe amplification (MLPA). We hypothesized that primary tumor and lymph node metastasis show similar CNV profiles, and CNV are more present in lymph node metastasis compared to primary tumor tissue. Samples from 43 (59.7%) patients could be analyzed. In total, 35 (83%), 26 (68%) and 8 (42%) patients had CNV in primary tumor, serum and lymph node metastasis, respectively. MYC, CCND1, ERBB2 and CCNE1 displayed the most frequent amplifications. In particular, CNV in ERBB2 was associated with aggressive tumor characteristics. CNV in both ERBB2 and TOP2A were risk factors for disease recurrence. The current findings show that CNV are present in various oncogenes and tumor suppressor genes in genomic DNA from primary tumor, lymph node metastasis and cfDNA from serum. CNV were more present in genomic DNA from primary tumor tissue compared to cfDNA from serum and genomic DNA from lymph node metastasis. Patients with CNV in ERBB2 and TOP2A are at increased risk for disease recurrence following RC. Further studies are necessary to validate, whether these genes may represent promising candidates for targeted-therapy. |
format | Online Article Text |
id | pubmed-7725833 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Nature Publishing Group UK |
record_format | MEDLINE/PubMed |
spelling | pubmed-77258332020-12-14 Copy number variations in primary tumor, serum and lymph node metastasis of bladder cancer patients treated with radical cystectomy Soave, Armin Kluwe, Lan Yu, Hang Rink, Michael Gild, Philipp Vetterlein, Malte W. Marks, Philipp Sauter, Guido Fisch, Margit Meyer, Christian P. Ludwig, Tim Dahlem, Roland Minner, Sarah Pantel, Klaus Steinbach, Bettina Schwarzenbach, Heidi Sci Rep Article The aim of the present study was to analyze copy number variations (CNV) of multiple oncogenes and tumor suppressor genes in genomic DNA from primary tumor tissue, lymph node metastasis and cell-free DNA (cfDNA) from serum of 72 urothelial carcinoma of bladder (UCB) patients treated with radical cystectomy (RC), using multiplex ligation-dependent probe amplification (MLPA). We hypothesized that primary tumor and lymph node metastasis show similar CNV profiles, and CNV are more present in lymph node metastasis compared to primary tumor tissue. Samples from 43 (59.7%) patients could be analyzed. In total, 35 (83%), 26 (68%) and 8 (42%) patients had CNV in primary tumor, serum and lymph node metastasis, respectively. MYC, CCND1, ERBB2 and CCNE1 displayed the most frequent amplifications. In particular, CNV in ERBB2 was associated with aggressive tumor characteristics. CNV in both ERBB2 and TOP2A were risk factors for disease recurrence. The current findings show that CNV are present in various oncogenes and tumor suppressor genes in genomic DNA from primary tumor, lymph node metastasis and cfDNA from serum. CNV were more present in genomic DNA from primary tumor tissue compared to cfDNA from serum and genomic DNA from lymph node metastasis. Patients with CNV in ERBB2 and TOP2A are at increased risk for disease recurrence following RC. Further studies are necessary to validate, whether these genes may represent promising candidates for targeted-therapy. Nature Publishing Group UK 2020-12-09 /pmc/articles/PMC7725833/ /pubmed/33298978 http://dx.doi.org/10.1038/s41598-020-75869-x Text en © The Author(s) 2020 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. |
spellingShingle | Article Soave, Armin Kluwe, Lan Yu, Hang Rink, Michael Gild, Philipp Vetterlein, Malte W. Marks, Philipp Sauter, Guido Fisch, Margit Meyer, Christian P. Ludwig, Tim Dahlem, Roland Minner, Sarah Pantel, Klaus Steinbach, Bettina Schwarzenbach, Heidi Copy number variations in primary tumor, serum and lymph node metastasis of bladder cancer patients treated with radical cystectomy |
title | Copy number variations in primary tumor, serum and lymph node metastasis of bladder cancer patients treated with radical cystectomy |
title_full | Copy number variations in primary tumor, serum and lymph node metastasis of bladder cancer patients treated with radical cystectomy |
title_fullStr | Copy number variations in primary tumor, serum and lymph node metastasis of bladder cancer patients treated with radical cystectomy |
title_full_unstemmed | Copy number variations in primary tumor, serum and lymph node metastasis of bladder cancer patients treated with radical cystectomy |
title_short | Copy number variations in primary tumor, serum and lymph node metastasis of bladder cancer patients treated with radical cystectomy |
title_sort | copy number variations in primary tumor, serum and lymph node metastasis of bladder cancer patients treated with radical cystectomy |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7725833/ https://www.ncbi.nlm.nih.gov/pubmed/33298978 http://dx.doi.org/10.1038/s41598-020-75869-x |
work_keys_str_mv | AT soavearmin copynumbervariationsinprimarytumorserumandlymphnodemetastasisofbladdercancerpatientstreatedwithradicalcystectomy AT kluwelan copynumbervariationsinprimarytumorserumandlymphnodemetastasisofbladdercancerpatientstreatedwithradicalcystectomy AT yuhang copynumbervariationsinprimarytumorserumandlymphnodemetastasisofbladdercancerpatientstreatedwithradicalcystectomy AT rinkmichael copynumbervariationsinprimarytumorserumandlymphnodemetastasisofbladdercancerpatientstreatedwithradicalcystectomy AT gildphilipp copynumbervariationsinprimarytumorserumandlymphnodemetastasisofbladdercancerpatientstreatedwithradicalcystectomy AT vetterleinmaltew copynumbervariationsinprimarytumorserumandlymphnodemetastasisofbladdercancerpatientstreatedwithradicalcystectomy AT marksphilipp copynumbervariationsinprimarytumorserumandlymphnodemetastasisofbladdercancerpatientstreatedwithradicalcystectomy AT sauterguido copynumbervariationsinprimarytumorserumandlymphnodemetastasisofbladdercancerpatientstreatedwithradicalcystectomy AT fischmargit copynumbervariationsinprimarytumorserumandlymphnodemetastasisofbladdercancerpatientstreatedwithradicalcystectomy AT meyerchristianp copynumbervariationsinprimarytumorserumandlymphnodemetastasisofbladdercancerpatientstreatedwithradicalcystectomy AT ludwigtim copynumbervariationsinprimarytumorserumandlymphnodemetastasisofbladdercancerpatientstreatedwithradicalcystectomy AT dahlemroland copynumbervariationsinprimarytumorserumandlymphnodemetastasisofbladdercancerpatientstreatedwithradicalcystectomy AT minnersarah copynumbervariationsinprimarytumorserumandlymphnodemetastasisofbladdercancerpatientstreatedwithradicalcystectomy AT pantelklaus copynumbervariationsinprimarytumorserumandlymphnodemetastasisofbladdercancerpatientstreatedwithradicalcystectomy AT steinbachbettina copynumbervariationsinprimarytumorserumandlymphnodemetastasisofbladdercancerpatientstreatedwithradicalcystectomy AT schwarzenbachheidi copynumbervariationsinprimarytumorserumandlymphnodemetastasisofbladdercancerpatientstreatedwithradicalcystectomy |